Compare EVEX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVEX | PHAT |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | 198 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.9M | 894.0M |
| IPO Year | N/A | 2019 |
| Metric | EVEX | PHAT |
|---|---|---|
| Price | $2.90 | $11.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $6.88 | ★ $19.83 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | $11,676.47 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $2.34 | $2.21 |
| 52 Week High | $7.70 | $18.31 |
| Indicator | EVEX | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 48.53 |
| Support Level | $2.86 | $10.47 |
| Resistance Level | $3.18 | $13.04 |
| Average True Range (ATR) | 0.15 | 0.92 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 53.76 | 50.64 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.